2015 Full Year Results Transatlantic Healthcare Technology Group - - PowerPoint PPT Presentation

▶

Aug 12, 2023 42 likes •402 views

2015 Full Year Results Transatlantic Healthcare Technology Group Focused on value creation through execution Franois R Martelet, M.D. Chief Executive Officer Mark Nanovich Interim CFO 7 April 2016 Disclaimer This present at ion is not an

SLIDE 1

2015 Full Year Results

Transatlantic Healthcare Technology Group

Focused on value creation through execution

François R Martelet, M.D. Chief Executive Officer Mark Nanovich Interim CFO 7 April 2016

SLIDE 2 This present at ion is not an offer or solicit at ion of an offer t o buy or sell securit ies. It is solely for use at t his invest or meet ing and is provided for informat ion only. This present at ion does not cont ain all t he informat ion t hat is or may be mat erial t o a prospect ive invest or (such as risk fact ors). By at t ending t he present at ion or by reading t he present at ion slides you agree t o be bound as follows: This present at ion has been prepared by Net S cient ific plc (t he “ Company” ), is st rict ly confident ial and is not , and should not be const rued as, a prospect us or list ing part iculars relat ing t o t he Company. This present at ion does not const it ute or form part of, and must not be const rued as, an

ffer or invit at ion t o subscribe for, underwrit e or ot herwise acquire, or a recommendat ion regarding, any securit ies of t he Company, nor should it or any part of it form t he basis of or be relied on in connect ion wit h (i) any cont ract t o purchase or subscribe for any securit ies of t he Company, or

(ii) any ot her cont ract or commit ment what soever. Not hing in t his present at ion shall be deemed t o be binding against , or t o creat e any obligat ions or commitment on t he part of, any prospect ive invest or or t he Company. The cont ent s of t his present at ion should not be considered t o be legal, t ax, invest ment or ot her advice, and any prospect ive invest or considering t he purchase of any securit ies of t he Company should consult wit h it s own counsel and advisers as t o all legal, t ax, regulat ory, financial and relat ed mat t ers concerning an invest ment in such securit ies and as t o t heir suit abilit y for such prospect ive invest or. This present at ion has been made t o you solely for your informat ion and background for discussion purposes only, and may be amended and supplement ed and must not be relied upon for t he purpose of ent ering int o any t ransact ion. This present at ion and it s cont ent s are confident ial and propriet ary t o t he Company, and no part of it or it s subj ect mat t er may be reproduced, redist ribut ed, passed on, or t he cont ent s ot herwise divulged, direct ly or indirect ly, t o any ot her person (excluding t he relevant person’ s professional advisers) or published in whole or in part for any purpose wit hout t he prior writ t en consent of t he Company. If t his present at ion has been received in error it must be ret urned immediat ely t o t he Company. This present at ion is not direct ed t o or int ended for dist ribut ion, or t ransfer, eit her direct ly or indirect ly t o, or use by, any person or ent it y t hat is a cit izen or resident or locat ed in any localit y, st at e, count ry or ot her j urisdict ion where such dist ribut ion, t ransfer, publicat ion, availabilit y or use would be cont rary t o law or regulat ion or which would require any regist rat ion or licensing wit hin such j urisdict ion. In part icular, neit her t his present at ion nor any copy hereof may be sent , or t aken, t ransmit t ed or dist ribut ed, direct ly or indirect ly, in or int o Aust ralia, Canada, Japan, or t he Unit ed S t at es (including it s t errit ories and dependencies, any st at e of t he Unit ed S t at es and t he Dist rict of Columbia) or t o any resident of Aust ralia, Canada or Japan. This present at ion is only being provided t o persons out side of t he Unit ed S t at es in reliance on exempt ions from t he US S ecurit ies Act of 1933, as amended (t he “ S ecurit ies Act ” ). This present at ion does not const it ut e or form a part of any offer or solicit at ion t o purchase or subscribe for securit ies in t he Unit ed S t at es. The securit ies referred t o herein or offered in connect ion wit h t his present at ion have not been, and will not be, regist ered under t he S ecurit ies Act . They may not be offered, sold, t ransferred, dist ribut ed or delivered, direct ly or indirect ly wit hin, int o or in t he Unit ed S t at es except pursuant t o an exempt ion from, or in a t ransact ion not subj ect t o, t he regist rat ion requirement s of t he S ecurit ies Act . No public offering of t he securit ies will t ake place in t he Unit ed S t at es. Neit her t he US S ecurit ies and Exchange Commission nor any securit ies regulat ory aut horit y of any st at e or ot her j urisdict ion of t he Unit ed S t at es has approved or disapproved of an invest ment in t he securit ies or passed on t he accuracy or adequacy of t he cont ent s of t his present at ion. Any represent at ion t o t he cont rary is a criminal offence in t he Unit ed S t at es. This communicat ion is direct ed at (i) persons out side t he Unit ed Kingdom, or, if t his present at ion is int ended for dist ribut ion in t he Unit ed Kingdom, (ii) solely t o (a) persons who have professional experience in mat t ers relat ing t o invest ment s falling wit hin Art icle 19(5) of t he Financial S ervices and Market s Act 2000 (Financial Promot ion) Order 2005, as amended (t he “ Order” ); (b) members or credit ors of a corporat e body wit hin t he meaning of art icle 43 of t he order; (c) t hose persons falling wit hin Art icle 49(2)(a) t o (d) of t he order; or (d) t hose persons t o whom it can ot herwise be dist ribut ed wit hout cont ravent ion of Art icle 21 of t he Financial S ervices and Market s Act 2000 or t o whom it may ot herwise lawfully be dist ribut ed (each, a “ relevant person” ). This present at ion must not be act ed or relied upon by persons ot her t han relevant persons. Any invest ment or invest ment act ivit y t o which t his communication relat es is available only t o (i) in t he Unit ed Kingdom, relevant persons and, (ii) in any member st at e of t he European Economic Area ot her t han t he Unit ed Kingdom, “ qualified invest ors” wit hin t he meaning of art icle 2(1)(e) of t he Prospect us Direct ive (Direct ive 2003/ 71/ EC), and will be engaged in only wit h such persons. This present at ion cont ains forward-looking st at ement s. These st at ement s may include t he words “ believe” , “ expect ” , “ ant icipat e” , “ int end” , “ plan” , “ est imat e” , “ proj ect ” , “ will” , “ may” , “ t arget ing” and similar expressions as well as st at ement s ot her t han st at ement s of hist orical fact s including, wit hout limit at ion, t hose regarding t he financial posit ion, business st rat egy, plans, t arget s and obj ect ives of t he management of t he Company for fut ure operat ions (including development plans and obj ect ives). S uch forward-looking st at ement s involve known and unknown risks, uncert aint ies and ot her import ant fact ors which may affect t he Company's abilit y t o implement and achieve t he economic and monet ary policies, budget ary plans, fiscal guidelines and ot her development benchmarks set out in such forward-looking st at ement s and which may cause act ual result s, performance or achievement s t o be mat erially different from fut ure result s, performance or achievement s expressed or implied by such forward-looking st at ement s. S uch forward-looking st at ement s are based on numerous assumpt ions regarding t he Company’ s present and fut ure policies and plans and t he environment in which t he Company will operat e in t he fut ure. Furt hermore, cert ain forward-looking st at ement s are based on assumpt ions or fut ure event s which may not prove t o be accurat e. The forward-looking st at ement s in t his present at ion speak only as of t he dat e of t his present at ion, and t he Company expressly disclaims t o t he fullest ext ent permit t ed by law any obligat ion or undert aking t o disseminat e any updat es or revisions t o any forward-looking st at ement s cont ained herein t o reflect any change in expect at ions wit h regard t heret o or any change in event s, condit ions or circumst ances on which any such st at ement s are based. Not hing in t he foregoing is int ended t o or shall exclude any liabilit y for, or remedy in respect of, fraudulent misrepresent at ion. The informat ion in t his present at ion has been verified by Net S cient ific only, and has been independent ly verified by any ot her person. No represent at ion or warrant y, express or implied, is made as t o t he fairness, accuracy or complet eness of t he present at ion and t he informat ion cont ained herein and no reliance should be placed on it . Informat ion in t his present at ion (including market dat a and st at ist ical informat ion) has been obt ained from various sources (including t hird part y sources) and t he Company does not guarant ee t he accuracy or complet eness of such informat ion. All proj ect ions, valuat ions and st at ist ical analyses are provided t o assist t he recipient in t he evaluat ion of mat t ers described herein. They may be based on subj ect ive assessment s and assumpt ions and may use one among alt ernat ive met hodologies t hat produce different result s and t o t he ext ent t hey are based on hist orical informat ion, t hey should not be relied upon as an accurat e predict ion of fut ure performance. No represent at ion is made as t o t he reasonableness of t he assumpt ions made wit hin or t he accuracy or complet eness of any modelling, scenario analysis or back-t est ing. The informat ion in t his present at ion is not int ended t o predict act ual result s and no assurances are given wit h respect t heret o. None of t he Company, it s advisers, connect ed persons or any ot her person accept s any liabilit y what soever for any loss howsoever arising, direct ly or indirect ly, from t his present at ion or it s cont ent s. All informat ion, opinions and est imat es cont ained herein are given as of t he dat e hereof and are subj ect t o change wit hout not ice. The financial informat ion referenced in t his present at ion was derived from financial est imat es and/ or st at ement s prepared in accordance wit h account ing principles generally accept ed in t he Unit ed Kingdom (“ UK GAAP” ). The financial dat a in t his present at ion are solely for your informat ion, as background for discussion purposes and may not be relied upon for t he purpose of ent ering int o any t ransact ion. The unaudit ed pro forma financial informat ion set out in t his present at ion is based on cert ain import ant assumpt ions and adj ust ment s and does not purport t o represent what our result s of operat ions act ually will be in any fut ure periods. This present at ion does not disclose all t he risks and ot her significant issues relat ed t o an invest ment in any securit ies of t he Company / any t ransact ions referred t o herein. In making any invest ment decision, prospect ive invest ors must rely on t heir own examinat ion of t he Company and t he t erms of any t ransact ion, including t he merit s and risks involved.

Disclaimer

SLIDE 3

NetScientific Group PLC

New Group CEO

Francois R. Martelet, M.D – 20 years industry experience

Realign focus on healthcare

Digital Health, Diagnostics & Therapeutics

Portfolio rationalisation

Divested non-core investments with significant savings

Reorganisation

High calibre CEO’ s recruited for Wanda, ProAxsis, Vortex, Glycotest

Fundraising

£18.2m fundraising

Finance

£23.2m available cash resource, divestment of non-core assets Portfolio

Vortex

Critical patent granted. Manufacturing partners selected to support placements

Wanda

S ignificant team scale up, new software releases

ProAxsis

Commercial launch of first lab-based immunoassay in Q3. New data released

Glycotest

Continued development of HCC panel and added board member

Glucosense

Development of the alpha prototype

Biotechnology Positive preliminary data showing strong T-cell responses in pre-cervical cancer

Full year results: highlights

2015 was a turnaround year for the Group

SLIDE 4

NetScientific Group PLC

Additional Board member

Professor S tephen S mith – distinguished clinician, ex-CEO and entrepreneur

New CFO

Ian Postlethwaite to j oin, ex-FD at Allergy Therapeutics. Lean PLC team in London Portfolio

Vortex

VTX-1 instrument to be shipped to leading US researches in Q2 for Beta testing

Wanda

Two new commercial agreements in Q1 – HRS & Dignity Health (Oncology)

ProAxsis

World class S cientific Advisory Board appointed

Glycotest

Medical Advisory board appointed

Biotechnology S igned a Cooperative Research and Development Agreement with the US National Cancer Institute to co-develop novel cancer immunotherapies through Phase II clinical trials

Post period-end highlights

SLIDE 5

Vijay Barathan, MD Chief Investment Officer Ian Postlethwaite CFO (start date TBD) Francois Martelet, MD CEO

Healthcare Investment Banker Peel Hunt and Piper Jaffray Medical Doctor NHS

Ernest Schneider Commercial-Legal Director

Partner Reynolds Porter Chamberlain and Mishcon De Reya Founder Schneider Page FD Allergy Therapeutics Senior finance positions as AFS, Ericsson, Philips Electronics CEO Topotarget CEO Avax Technologies Senior positions at Merck & CO, Novartis, Schering-Plough and Eli Lilly

PLC Group management team strong and focused

CEO, Chairman of GSK Chairman NHS London Rector Imperial College Fellow Royal Society & Academy

f Medical Sciences

President of Medtronic President of Lederle President of BMS Europe

Jonathan Paisner NED Barry Wilson NED Sir Richard Sykes Chairman

Founder LMN Capital Lawyer Mathias Gentle Page Hassan Board Shore Capital

Prof. Stephen Smith

NED

CEO Imperial College Trust Dean Medicine, Dentistry and health science University of Melbourne Founder Metris Therapeutics and GNI Group

PLC Board significant experience to leverage and build value

Strong and focused management team and Board

SLIDE 6

San Francisco & Philadelphia
ffices / 36 Employees

USA UK

Digital Health Diagnostics Therapeutics Digital Health Diagnostics

London HQ/ 8 employees
UK/ 12 Employees

Listing AIM (NSCI) Funds raised c.£48m

No. of Shares

51,075,695 Share price (6/ 4/ 2016) 72.5p Market Cap (6/ 4/ 2016) £37m Shareholders (>3% ) 45.1% Woodford Investment Management 18.1% Invesco Asset Management 9.2% JO Hambro 20.4% Azima Family Trusts

NetScientific’s mission is to change the paradigm of care in chronic diseases

SLIDE 7

Commercial st age Development st age

Gene Walther Steve Curd David Ribeiro Larry Cohen

Leadership Deputy Director Gates Foundation Chairman GenturaDx President diagnostics Novartis and Chiron CIO United Health COO WebMD COO NANTHEALTH CEO CareinSync Business Manager EU Pharmaxis Unit Director Pfizer Global product Director Solvay CEO Exalenz Bioscience CEO SenGenix CEO IVD Solutions President ITC VP J&J Product Cancer diagnostic instrument for isolation and collection of circulating tumour cells Advanced chronic disease management platform based on machine learning Respiratory diagnostic test for monitoring patients with Cystic Fibrosis and COPD Blood tests for liver diseases Business model Instrument and consumable cartridge sales Clinical research labs Software as a service Providers/ payors/ pharma Test kits and point of care device sales Pharma/ clinics/ home Lab sales CLIA labs Grant funding £1.6m £7.7m £1.0m £5.9m NetScientific Investment as at 31 Dec 15 £5.6m (£6.9m as at 31 Mar 16) £5.1m (£6.0m as at 31 Mar 16) £0.1m (£0.6m as at 31 Mar 16) £1.2m (£1.5m as at 31 Mar 16) NetScientific shareholding 95% 71.3% 56.5% 87.5% 7

Game changing portfolio with new management teams

SLIDE 8

2016 / 2017 – building value in PLC

Exit

Priority Portfolio

Growth Capital Pipeline

Capital returned to shareholders

Series A financings

IPO / M&A

H2 2016 2017

Global institutions, technology incubators, deep healthcare network 8

SLIDE 9

Financials – results for the year

2015 £’000 2014 £’000 Loss from Continuing operations 11,229 6,179 Loss from Discontinued operations 1,517 948 Loss for the year 12,746 7,127 Loss from Continuing operations R&D 7,256 3,098 G&A 3,182 2,495 Other costs 1,077 717 Tax credit/Income (286) (131) 11,229 6,179

SLIDE 10

Financials – balance sheet & cash flow

2015 £’000 2014 £’000 Balance Sheet - highlights Cash at bank ** 23,239 16,867 Investment in PDS 1,757 1,757 Net assets 24,583 18,696 ** Balance as at 31 March 2016 - £19.5m Cash flow Net proceeds Capital raising 17,147

Funds used in operations

(10,714) (6,631) Other (273) (2,189) Increase/(decrease) in cash 6,160 (8,820)

SLIDE 11

PLC has completed its turnaround

Re-structured, re-focused, portfolio rationalised – divested non-core assets
Highly experienced lean management team in London in place
Positive momentum in lead portfolio companies – talented CEOs in place to lead the next phase of

value creation with game-changing assets PLC is working on building shareholder value

Renewed IR/ PR effort to broaden the shareholder base in UK and US
Goal is to deliver value enhancing news flow in 2016 : commercial traction and external valuation

from portfolio company financings

Actively managing current portfolio to value realization including S

eries A for Wanda, ProAxsis and Glycotest

Summary and outlook

SLIDE 12

Vortex & Wanda

SLIDE 13

SLIDE 14

Executive summary

Research tools and diagnostics company developing a novel liquid biopsy

technology that could revolutionize cancer research, drug development, diagnosis, monitoring and treatment

$22B market opportunity*
Patented microfluidic technology yields intact circulating tumor cells (CTCs)
Outperforms competitors in key fields – purity (specificity) and collection efficiency

(sensitivity)

Significant growth opportunities as the product pipeline expands from research to

also providing clinical information from CTCs

* J.P. Morgan Liquid Biopsy Report – May 27, 2015

SLIDE 15

The Company

Formed in 2012 based on research done by PECASE (Presidential Early

Career Award for Science and Engineering) winner Dino Di Carlo at UCLA

Late stage development phase – placing Beta & KOL units in 2016
Exciting R&D presents near-term growth opportunities in the rapidly growing

liquid biopsy market

Placement of VTX-1 with key opinion leaders (KOLs), onboarding of sales

and marketing staff and critical publications will drive demand

New CEO appointed – Gene Walther experienced leader in diagnostics and

medical devices

SLIDE 16

Leadership team

Elodie Sollier-Christen, Ph.D

CSO & VP R&D

Michael Kochersperger

CTO & VP Engineering

President Chiron/Novartis

Diagnostics

CEO Gentura Dx
Deputy Director Bill & Melinda

Gates Foundation

Ph.D Microfluidics
UCLA, Stanford
Expertise in microdevices

for blood sample prep.

Director Orchid Biosciences
VP New Brunswick Scientific
VP BioNanomatrix
J&J

Gene Walther, MBA

CEO

Steven Crouse, MBA

CCO

SVP FreeSlate
Director BioRad
Invitrogen
Biosource

Bob Englert, MBA

VP Manufacturing

Abbott Laboratories
Biomedtrics
Pelikan Technologies

SLIDE 17

Circulating tumor cells (CTCs) detach from a solid tumor and enter the blood stream playing a crucial role in cancer metastasis. Challenges to CTC isolation

Extremely rare: 1-100 CTCs per mL of blood
Other cells: millions of WBCs and billions of RBCs per mL of

blood

Vortex liquid biopsy captures circulating tumor cells…

SLIDE 18

Technology

Cells enter the device and are

‘focused’ into an equilibrium position

CTCs selectively enter the

‘Vortex’

Red and white blood cells flow
ut of the system
Intact CTCs released for further

analysis in cytopathology, propagation, drug development, treatment selection/effectivity and next generation sequencing

12 patents, 3 granted, 6 licensed – starting internal IP
10 publications

SLIDE 19

VTX-1 Workflow

SLIDE 20

CTC Analysis (Viability, Purity, Automation)

Cancer Research
Patient Prognosis
Personalized Therapy
Drug Development & Testing

CTC Enumeration (Efficiency, Cost)

Early Stage Diagnosis
Patient Prognosis
Treatment Outcome Monitoring
Residual Disease

* JP Morgan liquid biopsy report – May 27, 2015

CTC potential

$22B market by 2020*

Cancer Research Personalized Medicine Drug Development Cancer Diagnostic Cancer Monitoring

SLIDE 21

Opportunities – focused growth

CTCs ctDNA

Enabling key applications beyond cancer research
Combining CTC isolation with new platforms

SLIDE 22

Cell affinity Filtration Active forces Inertial microfluidics

Marker independent Most cancers No pre-processing

Depends

High-purity Rapid processing

Depends

Large input volume Live cells Flexible collection Other body fluids Companies

J&J CellSearch, Biocept, Cynvenio Rarecell, Creatv Microtech Angle, Apocell Clearbridge, J&J/MGH

VTX-1 is potentially best in class technology…

SLIDE 23

Product overview

Name Vortex VTX-1 Liquid Biopsy System Key Dates Soft Research Market Launch, April 2016 Global Commercial Launch, Q1 2017 Instrument price ASP ~ $120,000 (TBC – pricing study) Cartridge price Target GP % ASP ~ $200 (TBC – pricing study) 80+% Key Partnerships Accel to manufacture first 5 units Gener8 selected as contract manufacturer for VTX-1 Symbient/Z-Microsystems for cartridge Sales Strategy Direct to user (US), academic and industry Internationally (TBD)

Cartridge bottom Gasket material Cartridge top with deep pocket

SLIDE 24

Commercial Milestones

2016 2017

Q1 Q2 Q3 Q4 Q1 Q2-4

Beta placements AACR soft launch (Research market) KOL placements Full commercial launch VTX-1 contract manufacturing Cartridge contract manufacturing Gener8 Z Microsystems

SLIDE 25

SLIDE 26

Executive summary

Chronic condition management company that aims to reduce hospitalization costs and improve patient quality of life New CEO hired – Steve Curd proven digital health leader $2B initial market opportunity – exponential growth* Patented systems developed from over 12 years of clinical research at UCLA Commercialisation underway – 2 new customers

*Investec analyst note

SLIDE 27

Leadership Team

27 Steve Curd, MBA

CEO

Mark Heinemeyer

CCO

Foad Dabiri, Ph.D

CTO

SLIDE 28

Opportunity: healthcare's trillion $ problem

75% of the $3.0 trillion fighting chronic

conditions

50% of patients treated for heart failure

are re-hospitalized within 6 months These readmissions cost the U.S. $17 billion/year

Even worse are the human costs. Patients suffering from chronic conditions

experience disabling and long-term symptoms. In addition, 7 out of every

10 deaths are a result of these costly and often preventable diseases

SLIDE 29

Value proposition

WANDA aims to reduce this trillion $ burden by preventing hospital admissions and reducing readmissions through a bifurcated consumer and clinical strategy

Predict Clinicians Intervene based on actionable insights Reduce readmission s Inform & Guide Reduce admissions Engage Collect data

SLIDE 30

How we are different

Science and research driven

Technology developed from multiple clinical trials - including 1,500 patient clinical

study

Strong IP position

True predictive analytics and machine learning Contextual data and real-time vitals Mobile application

Not typically used by analytics or RMS companies

Patient engagement/adherence driven by the worlds largest, most validated personality database Revenue generating

SLIDE 31

Uniquely positioned against competition

Analytics RMS Engagement

MD Revolution Accolade Tactico MDLive Sotera VitalConnect HealthCatalyst MedeAnalytics Cloud-MedX SyTrue

Sentrian Viterion

VivifyHealth ZypherLIFE

Omada

SLIDE 32

Business model – B2B

Enables ubiquitous care Engage, monitor and prioritize patients with chronic conditions, to improve efficiency & workflow Reduce hospitalizations and cost Delegate more care to the patient Provide clinicians with actionable insight Patient Engagement – Mobile App

Home Health system  Large hospital groups  Payers  Skilled nursing facilities 

Target customers:

SLIDE 33

Sales update - HRS

HR HRS

On One call h hi-tech nur nursing & rehab

Health Resource Solutions, Chicago-based home health agency
Works with more than 1,000 patients/month, will be using an app to keep tabs on its patients with CHF

and COPD

HRS is among a number of home health agencies turning to digital health to improve the post-

discharge process for patients with chronic conditions

$60/month/patient with an upfront $225/patient kit
In production now; estimated ramp up to > 50 patients/month

SLIDE 34

Business model: growth strategy

Targeting customers earlier in the value curve to have more impact Access pay-for-performance market through growth into population health

Stage A (early onset) Stage B Stage C

Currently engage patients after they have experienced a hospitalization

D2C

CHF Population Max impact

Stage D (late stage)

Economic impact

SLIDE 35

Milestones

2016 Goals Drivers

Participants registered 4,000

B2B sales ex. HRS
D2C early platform adopters

Revenue $800K

Oncoverse and HRS

Commercial agreements 4

Large hospital groups
Payers
Home health systems
Skilled nursing facilities

Wanda Health Management Releases 4

In-house R&D
Market research

Predictive Modules 3

In-house R&D

Oncoverse Releases 3

In-house R&D

Android & Apple iOS Mobile Releases 4

In-house R&D

SLIDE 36

NetScientific.net